UK-CAB 71: Broadly Neutralising Antibodies (bNABs), POPPY Sleep study feedback
Friday 24 January 2020
Programme
| 09.15-09.25 | Arrival, tea and refreshments |
| 09:30-10:00 | Welcome and introductions UK-CAB updates Company pre-meeting |
| 10:00-11:30 | Company meeting: ViiV Healthcare |
| 11.30-11.40 | Break |
| 11.40-12.40 | HIV broadly neutralising antibodies (bNAbs) and the RIO study – Simon Collins, HIV i-Base |
| 12.45-14.00 | Lunch |
| 14.00-16.00 | POPPY Sleep study community feedback – Alan Winston and Caroline Sabin |
| 16.00-16:10 | Break |
| 16:10 -16.40 | Conferences feedback – BHIVA, EACS |
| 16.40-17.00 | Members Updates Meeting reflection Any other business & reflection |
| 17.00 | Meeting close |
Slides and meeting report
HIV broadly neutralising antibodies (bNAbs) and the RIO study
Company meeting: ViiV Healthcare
POPPY Sleep study update
Meeting report (to follow)
Background reading
The Rise of Broadly Neutralizing Antibodies
https://www.avac.org/blog/rise-broadly-neutralizing-antibodies
bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges
http://i-base.info/htb/35260
Gilead announces licensing agreement for Rockefeller University bNAbs
http://i-base.info/htb/37084
POPPY Sleep Sub study
https://www.ucl.ac.uk/global-health/research/a-z/POPPY-sleep-sub-study
Research summary:
Very little is known about the effects, if any, being HIV positive and being on anti-HIV medication may have on sleeping and sleep patterns. The aims of this study are to see if sleep is affected by being HIV positive, and if any changes to sleep then affect other functions in the body such as brain function.
It is a sub-study of the POPPY (Pharmacokinetic and Clinical Observations in People Over Fifty) study and the aim is for 500 main study participants to join this sub-study. It is an observational study (does not require participants to take any specific medication) taking place at 7 hospitals in the UK and Ireland. It is anticipated it will take around 2 years to complete the visits on 500 participants. This sub-study is being funded by the National Institutes of Health in the USA.
The research involved a study visit at the clinic which is expected to take up to 2 hours. At this visit participants will undergo brain function (cognitive) tests, complete a study questionnaire, give a brief medical history regarding their sleep and have some clinical measurements taken. Participants will then be given 2 devices and a sleep diary to complete over 7 days.
The first device is an Actigraph which records physical activity and sleep/wake patterns and will be worn for 7 consecutive days and nights. The second device, which will be worn for only one of those nights, is a pulse oximeter which records the levels of oxygen in the blood. The participants will return the devices and diaries to clinic at the end of the 7 days and have a fasting blood sample taken.
HIV is not associated with sleep-disordered breathing – poster at BHIVA conference
https://www.bhiva.org/file/5ca73250cc0a7/P063.pdf
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.
This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.